Pierce™ Trifluoroacetic Acid (TFA), Sequencing grade
Pierce™ Trifluoroacetic Acid (TFA), Sequencing grade
Pierce™ Trifluoroacetic Acid (TFA), Sequencing grade
Pierce™ Trifluoroacetic Acid (TFA), Sequencing grade
Thermo Scientific™

Pierce™ Trifluoroacetic Acid (TFA), Sequencing grade

Thermo Scientific Pierce Trifluoroacetic Acid (TFA), Sequencing grade is manufactured and tested to meet strict specifications that ensure superior performanceRead more
Quantity:
100 g
10 x 1 mL
10 x 1 g
500 mL
Catalog number 28904
Price (JPY)
26,000
Each
Contact Us ›
Quantity:
10 x 1 mL
Request bulk or custom format
Thermo Scientific Pierce Trifluoroacetic Acid (TFA), Sequencing grade is manufactured and tested to meet strict specifications that ensure superior performance for use as an ion-pairing agent in reverse-phase peptide separations.

Features of Trifluoroacetic Acid (TFA), Sequencing grade:

High purity and exceptional clarity—allows sensitive, nondestructive peptide detection at low UV wavelengths in reverse-phase HPLC protein and peptide separation systems
High-performance packaging—TFA packaged under nitrogen in amber glass ampules or bottles with protective PTFE-lined fluorocarbon caps to ensure TFA integrity
Economical convenience—Choose the TFA format that works best for your application. In just a few seconds, 1 ml ampules can be used to prepare 1 liter of fresh 0.1% v/v trifluoroacetic acid solution for the mobile phase in reverse-phase chromatography

Applications of Trifluoroacetic Acid (TFA), Sequencing grade:
• Ion pair reagent for reverse-phase HPLC
• Protein/peptide sequencing
• Protein/peptide solubilizing agent
• Solid-phase peptide synthesis
• Amino acid analysis
• Making 0.1% solutions of trifluoroacetic acid (w/v vs. v/v)

Trifluoroacetic acid (TFA) is the most commonly used ion pairing agent for use in reverse-phase HPLC peptide separations because it sharpens peaks and improves resolution, is volatile and easily removed, has low absorption within detection wavelengths. It is manufactured to the highest specifications to ensure the integrity of your data, maximize sensitivity in your assay and to prolong the life of your equipment.

Making 0.1% Trifluoroacetic Acid Solutions:
For complex peptide separations, the key to success can be to vary selectivity. Varying mobile phase composition on the same column can change selectivity enough to resolve peptides that would otherwise overlap. Trifluoroacetic acid is the most frequently used modifier for peptide separations in reverse-phase HPLC. The TFA concentration usually specified is 0.1%. For reproducible separations from run-to-run or from lab-to-lab, it is essential to make TFA concentrations the same.

Trifluoroacetic acid concentration can and should be specified as either 'w/v' (weight/volume), or as 'v/v' (volume/volume). The w/v specification designates that the TFA is to be weighed and added to a volume of mobile phase (e.g. 0.1% TFA w/v requires one gram of TFA per liter). The v/v specification designates that the TFA is to be measured by volume (e.g. 0.1% TFA v/v requires one mL of TFA per liter).

Because the density of trifluoroacetic acid is 1.53 g/ml the difference between 0.1% TFA (w/v) and 0.1% TFA (v/v) is more than 50%. For the sake of reproducibility, it is essential for authors of a method to specify, and for users of a method to know, whether the TFA concentration is given as 'w/v' or 'v/v'.

Related Products
Pierce™ Trifluoroacetic Acid (TFA), Sequencing grade
For Research Use Only. Not for use in diagnostic procedures.
Specifications
Name NoteTrifluoroacetic Acid (TFA)
Physical FormLiquid
Recommended StorageStore in original container protected from direct sunlight in a dry, cool and well-ventilated area, between the following temperatures: 20 to 25°C.
Percent Purity99.5% (TFA)
Quantity10 x 1 mL
Unit SizeEach

Citations & References (4)

Citations & References
Abstract
Super-resolution proximity labeling with enhanced direct identification of biotinylation sites.
Authors:Shin S,Lee SY,Kang MG,Jang DG,Kim J,Rhee HW,Kim JS
Journal:Communications biology
PubMed ID:38724559
Promiscuous labeling enzymes, such as APEX2 or TurboID, are commonly used in in situ biotinylation studies of subcellular proteomes or protein-protein interactions. Although the conventional approach of enriching biotinylated proteins is widely implemented, in-depth identification of specific biotinylation sites remains challenging, and current approaches are technically demanding with low yields. ... More
Kinetic reaction modeling for antibody-drug conjugate process development.
Authors:Andris S,Seidel J,Hubbuch J
Journal:Journal of biotechnology
PubMed ID:31557498
By combining the specificity of monoclonal antibodies (mAbs) and the efficacy of cytotoxic drugs in one molecule, antibody-drug conjugates (ADCs) form a promising class of anti-cancer therapeutics. This is emphasized by around 65 molecules in clinical trials and four marketed products. The conjugation reaction of mAbs with small-molecule drugs is ... More
The impact of glycosylation on monoclonal antibody conformation and stability.
Authors:Zheng K,Bantog C,Bayer R
Journal:mAbs
PubMed ID:22123061
Antibody glycosylation is a common post-translational modification and has a critical role in antibody effector function. The use of glycoengineering to produce antibodies with specific glycoforms may be required to achieve the desired therapeutic efficacy. However, the modified molecule could have unusual behavior during development due to the alteration of ... More
Automated multi-attribute method sample preparation using high-throughput buffer exchange tips.
Authors:Ogata Y,Quizon PM,Nightlinger NS,Sitasuwan P,Snodgrass C,Lee LA,Meyer JD,Rogers RS
Journal:Rapid communications in mass spectrometry : RCM
PubMed ID:34783086
RATIONALE: The multi-attribute method (MAM) has become a valuable mass spectrometry (MS)-based tool that can identify and quantify the site-specific product attributes and purity information for biotherapeutics such as monoclonal antibodies (mAbs) and fusion molecules in recent years. As we expand the use of the MAM at various stages of ... More